Triphenyl phosphate

Synonyms: 磷酸三苯基酯
Triphenyl phosphate 是一种口服有效且可穿透血脑屏障的芳基有机磷酸酯类阻燃剂和内分泌干扰物,它通过氧化应激破坏线粒体动力学平衡、诱发过度线粒体自噬 (mitophagy) 和凋亡 (apoptosis) 最终导致心肌纤维化,在脑部通过扰乱肠道菌群激活 NF-κB 炎症通路、改变色氨酸代谢并升高神经毒素从而诱发焦虑抑郁样行为,在骨骼与生殖系统分别通过抑制 MAPK/ERK 通路和激活 JNK 信号阻碍成骨细胞分化并引发生殖细胞凋亡,并在脂肪与胎盘组织中通过激活 PI3K/AKT-PPARγ 轴促进脂质蓄积、经由 MAOA/ROS/NF-κB 级联反应扰乱胎盘代谢,损害子代神经发育。
产品编号: MS-N30854 纯度: 98.0% CAS No.: 115-86-6 分子式: C18H15O4P 分子量: 326.28
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价

产品描述

Triphenyl phosphate 是一种口服有效且可穿透血脑屏障的芳基有机磷酸酯类阻燃剂和内分泌干扰物,它通过氧化应激破坏线粒体动力学平衡、诱发过度线粒体自噬 (mitophagy) 和凋亡 (apoptosis) 最终导致心肌纤维化,在脑部通过扰乱肠道菌群激活 NF-κB 炎症通路、改变色氨酸代谢并升高神经毒素从而诱发焦虑抑郁样行为,在骨骼与生殖系统分别通过抑制 MAPK/ERK 通路和激活 JNK 信号阻碍成骨细胞分化并引发生殖细胞凋亡,并在脂肪与胎盘组织中通过激活 PI3K/AKT-PPARγ 轴促进脂质蓄积、经由 MAOA/ROS/NF-κB 级联反应扰乱胎盘代谢,损害子代神经发育。

生物实验数据

生物活性 Triphenyl phosphate is an orally effective aryl organophosphate flame retardant and endocrine disruptor capable of crossing the blood-brain barrier that disrupts mitochondrial dynamics balance via oxidative stress, induces excessive mitophagy and apoptosis, ultimately leading to myocardial fibrosis; in the brain, it activates the NF-κB inflammatory pathway by disturbing gut microbiota, alters tryptophan metabolism, and elevates neurotoxins, thereby inducing anxiety- and depression-like behaviors; in the skeletal and reproductive systems, it inhibits osteoblast differentiation and triggers germ cell apoptosis by suppressing the MAPK/ERK pathway and activating JNK signaling, respectively; and in adipose and placental tissues, it promotes lipid accumulation by activating the PI3K/AKT-PPARγ axis and disrupts placental metabolism via the MAOA/ROS/NF-κB cascade, impairing offspring neurodevelopment.
IC50 & Target

IL-6

 

体外研究
(In Vitro)

Triphenyl phosphate (10-100 μM; 48 h) 呈剂量依赖性抑制 MC3T3-E1 成骨细胞的迁移。
Triphenyl phosphate (0-100 μM; 24-120 h) 呈剂量和时间依赖性降低 MC3T3-E1 成骨细胞的增殖能力与存活率。
Triphenyl phosphate (10-40 μM; 24 h) 呈剂量依赖性抑制 MC3T3-E1 成骨细胞的侵袭与迁移。
Triphenyl phosphate (10-40 μM; 48 h) 可抑制 MC3T3-E1 成骨细胞中 MAPK 信号通路的 MEK/ERK 轴,并改变 EMT 相关蛋白的表达,且这些效应可被 MEK/ERK 激活逆转。
Triphenyl phosphate (40 μM; 48 h) 可下调 MC3T3-E1 成骨细胞中 NR3C1、IGF1R、MAP3K1、BRAF、WNK4 和 CNR2 基因的表达。
Triphenyl phosphate (50-150 μM) 可显著升高 H9c2 心肌细胞内的 ROS 水平。
Triphenyl phosphate (150 μM) 可降低 H9c2 心肌细胞中 MitoTracker Red 的荧光强度,表明线粒体形态受损。
Triphenyl phosphate (150 μM) 可增强 H9c2 心肌细胞中 LysoTracker Green 的荧光强度,提示溶酶体活性发生改变。
Triphenyl phosphate (150 μM) 可显著降低 H9c2 心肌细胞中具有高线粒体膜电位的细胞占比。
Triphenyl phosphate (150 μM) 可上调 H9c2 心肌细胞中线粒体自噬相关蛋白 Parkin、Pink1 和 LC3II/I 的表达。
Triphenyl phosphate (150 μM) 可显著提高 H9c2 心肌细胞的凋亡率。
Triphenyl phosphate (3.3-33 μM; 48 h) 可通过 MAOA 介导的氧化应激激活 NFκB,从而干扰人滋养层 JEG-3 细胞中的色氨酸代谢,在低至 3.3 μM 的浓度作用 48 h 时即可观察到相关效应。
Triphenyl phosphate (10 μM; 10 days) 可诱导分化中的 3T3-L1 前脂肪细胞出现显著的甘油三酯蓄积和脂滴形成。
Triphenyl phosphate (0.1-10 μM; 10 days) 可促进 3T3-L1 前脂肪细胞的成脂分化,其中 10 μM 浓度可显著上调关键成脂基因与蛋白的表达,并通过增强脂质合成与脂解作用破坏脂质稳态。
Triphenyl phosphate (10 μM; 10 days) 可诱导分化中的 3T3-L1 前脂肪细胞发生脂质代谢紊乱,改变多种脂质种类的水平并破坏关键代谢通路。
Triphenyl phosphate (10 μM; 10 days) 可改变分化中的 3T3-L1 前脂肪细胞的全局基因表达,激活 PPAR 信号通路与脂肪酸代谢,从而促进脂质积累和脂肪细胞分化。
Triphenyl phosphate (10 μM; 10 days) 可在分化中的 3T3-L1 前脂肪细胞中激活 PI3K/AKT 信号通路,且该激活作用是 TPHP 诱导脂质积累和成脂分化所必需的,因为使用 LY294002 进行抑制可逆转这些效应。

Cell Migration Assay

Cell Line: murine pre-osteoblastic MC3T3-E1 cells
Concentration: 10, 25, 50, 100 μM
Incubation Time: 48 h
Result: Inhibited MC3T3-E1 cell migration in a concentration-dependent manner, with significant reductions in migration rate observed at 10, 25, 50, and 100 μM compared to control.

Cell Invasion Assay

Cell Line: murine pre-osteoblastic MC3T3-E1 cells
Concentration: 10, 20, 40 μM
Incubation Time: 24 h
Result: Significantly suppressed MC3T3-E1 cell invasion and migration in a concentration-dependent manner, with significant reductions in relative cell count observed at 10, 20, and 40 μM compared to control.

Western Blot Analysis

Cell Line: murine pre-osteoblastic MC3T3-E1 cells
Concentration: 10, 20, 40 μM (single treatment); 40 μM (co-treatment with 1 μM C16-PAF (MS-W09636) or 10 μM MEK-IN-6 (MS-K67698))
Incubation Time: 48 h
Result: Significantly decreased phosphorylation levels of p-MEK and p-ERK1/2 (with no change to p-P38 or p-JNK), upregulated E-Cadherin expression, and downregulated N-Cadherin expression.
Reversed these changes when co-treated with the MEK/ERK activator C16-PAF, restoring p-MEK and p-ERK1/2 phosphorylation and normalizing E-Cadherin and N-Cadherin levels.
Did not reverse the effects when co-treated with MEK inhibitor MEK-IN-6.

Real Time qPCR

Cell Line: murine pre-osteoblastic MC3T3-E1 cells
Concentration: 40 μM
Incubation Time: 48 h
Result: Significantly downregulated the mRNA expression levels of NR3C1, IGF1R, MAP3K1, BRAF, WNK4, and CNR2 compared to the control group.
体内研究
(In Vivo)

Triphenyl phosphate (5-50 mg/kg;口服;每日;连续 30 天) 会在 C57BL/6 J 小鼠中诱导剂量依赖性心脏毒性,其中 50 mg/kg 剂量会引发显著的心脏纤维化、氧化应激、线粒体功能障碍、线粒体自噬及心肌细胞凋亡。
Triphenyl phosphate (0.5-2 mg/kg;口服;每日;妊娠第 0 天至第 12 天) 可诱导妊娠 C57BL/6 小鼠的胎盘氧化应激,激活炎症因子并扰乱色氨酸代谢。
Triphenyl phosphate (1-150 mg/kg;口服;每日一次;连续 60 天) 可诱导性别特异性脂质代谢紊乱,并通过剂量依赖性地增加腹股沟脂肪组织系数、促进脂肪细胞肥大以及上调成脂和脂质代谢相关基因,促进雄性小鼠肥胖,但对雌性小鼠的脂肪组织形态无显著影响。
Triphenyl phosphate (1-500 μg/L;暴露于钾溶液;72 h) 可通过破坏 JNK 信号通路在秀丽隐杆线虫中诱导浓度依赖性生殖毒性。
Triphenyl phosphate (0.89-9.19 μg/kg;口服;每日一次;28 周) 通过破坏肠-脑轴诱导雌性 BALB/c 小鼠出现显著的焦虑样和抑郁样行为,包括肠道菌群失调、全身氧化应激与炎症反应,以及前额叶皮层代谢和信号通路紊乱。

Animal Model: C57BL/6 J (adult male, 20-25 g)
Dosage: 5 mg/kg; 50 mg/kg
Administration: p.o.; daily; 30 days
Result: Induced disordered myocardial cell arrangement and increased eosinophilic cardiomyocytes at 50 mg/kg.
Elevated serum creatine kinase isoenzymes (CK-MB) and lactate dehydrogenase (LDH) levels significantly at 50 mg/kg.
Increased heart malondialdehyde (MDA) levels, while decreased superoxide dismutase (SOD) and serum glutathione peroxidase (GSH-Px) activities at 50 mg/kg.
Caused irregular cardiomyocyte mitochondrial shapes and disordered cristae at 50 mg/kg.
Decreased protein expression of mitochondrial fusion/fission factors (Mfn1, Mfn2, Opa1, Drp1, Fis1) significantly at 50 mg/kg.
Induced autophagosomes in cardiomyocytes, with increased protein expression of Parkin, Pink1, and LC3II/I at 50 mg/kg.
Increased TUNEL-positive apoptotic cardiomyocytes at 50 mg/kg.
Increased protein expression of Bax, CytC, and Cleaved-Caspase 3, decreased Bcl-2 expression, and increased Cleaved-Caspase 9 expression at 50 mg/kg.
Increased cardiac collagen deposition, with increased protein expression of Wnt, β-catenin, p-β-catenin, collagen I, collagen III, CTGF, and fibronectin at 50 mg/kg.
Showed no significant changes in myocardial histopathology, serum CK-MB/LDH levels, oxidative stress markers, mitochondrial structure/factor expression, or cardiac fibrosis markers at 5 mg/kg.
Increased Cleaved-Caspase 9 protein expression significantly, with no change in TUNEL-positive apoptotic cells at 5 mg/kg.
Animal Model: C57BL/6 (6-8 weeks old, female, pregnant)
Dosage: 0.5 mg/kg; 1 mg/kg; 2 mg/kg
Administration: p.o.; daily; E0 to E12
Result: Increased placental GSH to ~100 μmol/g, MDA to ~4 nmol/mgprot, and SOD vitality to ~150 U/mgprot at 2 mg/kg.
Increased placental MDA to ~3 nmol/mgprot and decreased SOD vitality to ~100 U/mgprot at 1 mg/kg.
Increased placental NFκB, IL6, MAOA, and KYNU gene expression, and decreased TPH1 and DDC gene expression at 0.5 mg/kg.
Increased placental NFκB, TNFα, IL6, MAOA, KYNU, and IDO1 gene expression, and decreased TPH1 and DDC gene expression at 1 mg/kg.
Increased placental NFκB, TNFα, IL6, MAOA, KMO, and KYNU gene expression, and decreased TPH1 and DDC gene expression at 2 mg/kg.
Increased placental NFκB, IDO1, and MAOA protein expression, and decreased TPH1 protein expression at 0.5 mg/kg.
Increased placental NFκB, TNFα, IL6, IDO1, TDO2, and MAOA protein expression, and decreased TPH1 protein expression at 1 mg/kg.
Increased placental NFκB, TNFα, IL6, IDO1, TDO2, and MAOA protein expression, and decreased TPH1 protein expression at 2 mg/kg.
Decreased placental tryptophan to ~25 μg/g FW and 5-HTP to ~0.015 μg/g FW at 1 mg/kg.
Increased placental serotonin to ~0.15 μg/g FW, 5-HIAA to ~0.3 μg/g FW, and KYN to ~25 μg/g FW at 1 mg/kg.
Showed a trend toward increased 3-HK levels at 1 mg/kg.
Animal Model: BALB/c (male, female, 3 weeks old at study start, oral exposure to triphenyl phosphate for 60 days to induce lipid metabolism disorder)
Dosage: 1 mg/kg/day; 10 mg/kg/day; 150 mg/kg/day
Administration: p.o.; daily; 60 days
Result: Increased inguinal adipose tissue coefficient in a dose-dependent manner in male mice.
Induced significant adipocyte hypertrophy across all doses in male mice, with mean adipocyte area significantly larger than control.
Increased serum total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) levels in male mice treated with 150 mg/kg/day, while all doses reduced serum triglyceride (TG) levels in male mice.
Upregulated PPARγ mRNA expression in a dose-dependent manner in male mice.
Upregulated chemerin mRNA expression in male mice treated with 150 mg/kg/day.
Upregulated lipid synthesis-related genes (Pck1, PDK, ChERBP) and lipolytic genes (Lipe, MGL) in male mice.
Showed an upward trend in serum TG, TC, HDL-C, and low-density lipoprotein cholesterol (LDL-C) levels in female mice treated with 150 mg/kg/day, with no significant changes in inguinal adipose tissue coefficient or adipocyte size compared to control.
Animal Model: wild-type Bristol N2; MT1079/egl-15 (n484) X; VC1089/mkk-4 (ok1545) X; VC822/kgb-2 (gk361) IV; JT366/vhp-1(sa366) II (synchronized L1-stage larvae)
Dosage: 1 μg/L, 10 μg/L, 100 μg/L, 500 μg/L
Administration: exposure in K+ solution; daily feeding; 72 hours
Result: Reduced mean lifespan by 1.65% (1 μg/L), 12.47% (10 μg/L), 13.3% (100 μg/L), and 25.22% (500 μg/L) relative to controls.
Determined 10-day LC50 as 575.47 μg/L (95% CI: 450.58-819.39 μg/L).
Reduced germ cell counts in the mitotic zone, transition zone, and meiotic prophase by 37.5%/41.0% (1 μg/L/500 μg/L), 30.2%/28.9%, and 36.9%/38.5% respectively.
Increased gonadal apoptotic cell count by 17.2% (1 μg/L), 77.6% (10 μg/L), 133.2% (100 μg/L), and 138.9% (500 μg/L) relative to controls.
Reduced uterine embryo count by 14.2% (1 μg/L), 18.2% (10 μg/L), 18.1% (100 μg/L), and 21.8% (500 μg/L) relative to controls.
Reduced total progeny count by 10.66% (1 μg/L), 13.94% (10 μg/L), 15.25% (100 μg/L), and 17.39% (500 μg/L) relative to controls.
Downregulated transcript levels of egl-15, dlk-1, mkk-4, kgb-2, and vhp-1, while upregulated kgb-1 in 500 μg/L exposed wild-type worms.
Increased gonadal apoptotic cell counts significantly higher than in exposed wild-type worms, and reduced uterine embryo counts and total progeny counts significantly lower than in exposed wild-type worms in mutant strains exposed to 1 μg/L or 500 μg/L TPHP.
Animal Model: BALB/c (female, 3 weeks old, 15−18 g)
Dosage: 0.89 μg/kg/day; 9.19 μg/kg/day
Administration: p.o.; daily; 28 weeks
Result: Reduced distance traveled in the central area by 67.8%, reduced time spent moving in the central area by 64.1%, significantly reduced upright behavior count, and significantly reduced grooming behavior count (9.19 μg/kg/day, open field test).
Reduced open arm entry frequency by 2.1-fold, reduced open arm retention time by 84.1% (9.19 μg/kg/day, elevated plus maze test).
Reduced sucrose preference index by 40.1% (9.19 μg/kg/day, sucrose preference test).
Reduced uric acid levels, reduced 5-hydroxytryptophan levels, elevated quinolinic acid levels, elevated glutamate levels, significantly elevated reactive oxygen species, nitric oxide, and malondialdehyde levels, upregulated catalase and superoxide dismutase expression, and increased NF-κB p65 and pro-inflammatory factors (TNF-α, IL-1β, IL-6) (9.19 μg/kg/day, prefrontal cortex).
Decreased relative abundance of Bacteroidota, increased Firmicutes, significantly reduced relative abundance of norank_f_Muribaculaceae, Lactobacillus, Alloprevotella, Bacteroides, and g_Akkermansia, significantly increased Lachnospiraceae_NK4A136_group, significantly increased Chao1 index, and showed β-diversity compositional differences from controls (9.19 μg/kg/day, gut microbiota).
Reduced xanthine levels, elevated uric acid levels, reduced 5-hydroxytryptophan levels, and significantly reduced acetic acid, propionic acid, and butyric acid levels.
Significantly upregulated quinolinic acid and glutamate levels, significantly downregulated xanthine, 5-hydroxytryptophan, acetic acid, propionic acid, and butyric acid levels, significantly elevated reactive oxygen species, nitric oxide, malondialdehyde, TNF-α, IL-1β, IL-6, and NF-κB p65 levels, and reached a mean level of 2.09 ng/mL (9.19 μg/kg/day, serum).
Significantly reduced time spent moving in the central area and reduced upright behavior count (0.89 μg/kg/day, open field test).
Showed 1208 upregulated and 1382 downregulated genes relative to controls, altered NF-κB signaling pathway and leukocyte transendothelial migration pathways, and disrupted purine and tryptophan metabolism pathways with trends matching the high-dose group (0.89 μg/kg/day, prefrontal cortex).
Mirrored high-dose group trends but most changes were not statistically significant (0.89 μg/kg/day, gut microbiota).
Reached a mean level of 0.36 ng/mL (0.89 μg/kg/day, serum).
性状 固体
颜色 White to off-white

化学信息

分子量 326.28
分子式 C18H15O4P
CAS No. 115-86-6
别名 磷酸三苯基酯

储存&溶解度

储存方式

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (306.49 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.0649 mL15.3243 mL30.6485 mL76.6213 mL
5 mM0.6130 mL3.0649 mL6.1297 mL15.3243 mL
10 mM0.3065 mL1.5324 mL3.0649 mL7.6621 mL
15 mM0.2043 mL1.0216 mL2.0432 mL5.1081 mL
20 mM0.1532 mL0.7662 mL1.5324 mL3.8311 mL
25 mM0.1226 mL0.6130 mL1.2259 mL3.0649 mL
30 mM0.1022 mL0.5108 mL1.0216 mL2.5540 mL
40 mM0.0766 mL0.3831 mL0.7662 mL1.9155 mL
50 mM0.0613 mL0.3065 mL0.6130 mL1.5324 mL
60 mM0.0511 mL0.2554 mL0.5108 mL1.2770 mL
80 mM0.0383 mL0.1916 mL0.3831 mL0.9578 mL
100 mM0.0306 mL0.1532 mL0.3065 mL0.7662 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用,-20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

磷酸三苯基酯 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础